immunofluorescence reagents
  • Biotime to Inaugurates Academic Exchange Center in Xiamen
    Biotime to Inaugurates Academic Exchange Center in Xiamen June 09, 2022
    On June 6, 2022, the Opening Ceremony of Biotime Academic Exchange Center was successfully held. Associate Dean of Shanghai Academy of Experimental Medicine, President of the National Association of Health Industry and Enterprise Management, Professor Song Haibo, Director of the Fujia Provincial Center For Clinical Laboratory, President of the Fujian Medical Association, Chen Falin, Xiamen University Life Sciences School Professor, Director of the Xiamen University - Biotime Research Center for Translational Medicine Zhang Yongyou and other guests, Chairman of Biotime Zhang Guofeng, Co-CEO Yin Peng, Vice General Manager Huang Jianguo and Zhuang Yanghuang and other business leaders attended the ceremony. Vice General Manager Zhuang Yanghuang led the ceremony Vice General Manager Zhuang said that Biotime Academic Exchange Center is expected to create opportunities and promote exchanges for the experts across the country, and this is also an opportunity for us, to do our best and strive for better future. Professor Song Haibo, President of the Fujian Medical Association Chen Falin, Deputy Director of Xiamen University School of Public Health, Director of the Center for Clinical Laboratories of Xiamen Humanity Hospital, Zhang Zhongying, together with Co-CEO of Biotime Yin Peng officially unveiled the commemorative plaque of the Biotime Academic Exchange Center. Co-CEO of Biotime Yin said that Biotime Academic Exchange Center is a platform at a higher level among leading experts and research communities at university, utilize Biotime’s production capacity to transform R&D achievements into product, as the mission we believe and keep pursuing,“Technology for Health” Director of the Fujian Provincial Center For Clinical Laboratory, President of the Fujian Medical Association, Chen Falin delivers the opening speech On the afternoon of June 6, the 1rst Session of Academic Salon was held.Director Chen said that productivity blends with creativity is a necessity in the development of Medical Laboratory, the establishment of Biotime Academic Exchange Center is to better apply the In-Vitro Diagnostic products into practice. Co-CEO of Biotime Yin Peng shares the trend in Translational Medicine and Biotime’s technology platforms and products Xiamen University Life Sciences School Professor, Director of the Xiamen University - Biotime Research Center for Translational Medicine Zhang Yongyou shares the product development of In-Vitro Diagnostic product with AI-Powered Design Biotime Academic Exchange Center provides a higher level platform for leading experts, exerts its will and capability on In-Vitro Diagnostic industry and takes the lead to construct a sustainable ecosphere and advance the combination of production and product development.
    View More
  • Biotime to Invest 180 Million Dollars in POCT Industrial Park for New Diagnostic Production, Research and Development
    Biotime to Invest 180 Million Dollars in POCT Industrial Park for New Diagnostic Production, Research and Development June 06, 2022
    On June 6, 2022, the Foundation Laying Ceremony of Biotime POCT Industrial Park Constructional Project was successfully held. Vice Mayor of Xiamen Government Huang Xiaozhou, Director of the Committee of Haicang Taiwanese-invested Investment Zone, Governor of the Haicang District Gong Jianyang, Associate Dean of Shanghai Academy of Experimental Medicine, President of the National Association of Health Industry and Enterprise Management, Professor Song Haibo and other leaders and guests, Chairman of Biotime Zhang Guofeng, Co-CEO Yin Peng, Vice General Manager Huang Jianguo and Zhuang Yanghuang and other business leaders witnessed this important moment. the Foundation Laying Ceremony of Biotime POCT Industrial Park Constructional Project the Chairman of Biotime, Zhang Guofeng delivers the opening speech The Chairman Zhang said that Biotime powered by innovation and stick with pragmatic approach since it was established, we believe and keep pursuing the mission of “Technology for Health” . Biotime have been listed in the “little giant” Enterprises of the Ministry of Industry and Information Technology and awarded as the “High-Tech Enterprise” and many others. With strong government support and Biotime’s own effort, it has now became the core drives in the fight against the coronavirus pandemic. This project marked a new chapter for Biotime, it will raise the capacity for pursuing product development, have a greater efficiency to increase output, construct a sustainable ecosphere for the industry and benefit in all aspects. This special time provide Biotime an extraordinary opportunity and we will actively take action and remain persistent and determined in our role in the industry and society. Deputy Director of the Committee of Haicang Taiwanese-invested Investment Zone, Zhang Chunjie delivers the speech Director of Xiamen Administration for Market Regulation, Xu Guohua delivers the speech Associate Dean of Shanghai Academy of Experimental Medicine, President of the National Association of Health Industry and Enterprise Management, Song Haibo delivers the speech the Foundation Laying Ceremony of Biotime POCT Industrial Park Constructional Project Biotime POCT Industrial Park is located in the southwest of the intersection of Maolin Road and Haixiang Avenue in Haicang District. It is divided into two plots and it covers a total area of about 86855.743 square metres, of which 35587.110 square metres is used for Plot A, and 51268.633 square metres for the Plot B. A total investment of nearly 180 million dollars is expected to be made in the industrial park by 2024. Rendering of Biotime POCT Industri...
    View More
  • Biotime's SARS-CoV-2 Antigen Rapid Qualitative Test has received approval from the China's National Medical Products Administration (NMPA)
    Biotime's SARS-CoV-2 Antigen Rapid Qualitative Test has received approval from the China's National Medical Products Administration (NMPA) May 23, 2022
    May 20, 2022, Biotime announced that its SARS-CoV-2 Antigen Rapid Qualitative Test has received approval from the China's National Medical Products Administration (NMPA). The details are as follows: The SARS-CoV-2 Antigen Rapid Qualitative Test has also obtained CE mark for self-testing, which is another effective tool for the company to actively support global anti-epidemic. It can be operated by individuals who collect the front nasal swab sample by themselves, and the result can be quickly delivered in 20-30 minutes. Since the outbreak of COVID-19, Biotime as a global innovation-driven healthcare company has fully integrated its business and global resources with timely response and actively undertaking the social responsibilities in combating COVID-19 pandemic control and minimizing its impact. Biotime has developed a growing number of diagnostic solutions that help to diagnose and detect the infection, and we will continue to play our role and increase production to support availability of tests globally.
    View More
  • Biotime's COVID-19 Ag & FluA/B Combo Test Obtains CE Mark for Self-testing
    Biotime's COVID-19 Ag & FluA/B Combo Test Obtains CE Mark for Self-testing May 18, 2022
    Biotime announced today that, it had now achieved CE Marking for its COVID-19 Ag & Flu A/B Combo Test from the European certification body CeCert to be used as a consumer self-test in the European Union (EU) and other regions that recognized the CE Mark. The details are as follows:  The test detects N protein from SARS-CoV-2, influenza A and influenza B directly from a nasal swab with results in 15 minutes from sample application in people with COVID-19 symptoms or influenza A or influenza B infection. The test has the advantage of being consistent in sensitivity and easy handling, it well meets the needs of epidemic prevention and control at home in various countries. Biotime will keep supporting the cause of global COVID-19 prevention and control, and actively respond to the market demand for testing products in COVID-19.
    View More
  • Biotime's SARS-CoV-2 Antigen Test Obtains CE Mark for Self-testing
    Biotime's SARS-CoV-2 Antigen Test Obtains CE Mark for Self-testing March 16, 2022
    Biotime's SARS-CoV-2 Antigen test obtains CE mark for self-testing, the details are as follows: The SARS-CoV-2 Antigen Rapid Qualitative Test that has completed CE certification, this time is another effective tool for the company to actively support global anti-epidemic. It can be operated by individuals who collect the front nasal swab sample by themselves, and the result can be quickly obtained in 20-30 minutes, which is convenient for individuals and families to quickly detect Covid-19, well meets the needs of epidemic prevention and control at home in various countries, and further enriches the Biotime COVID-19 Solution. The company will fully support the cause of global COVID-19 prevention and control, and actively respond to the market demand for testing products in COVID-19.
    View More
  • Biotime Donated COVID-19 Test to Hong Kong
    Biotime Donated COVID-19 Test to Hong Kong March 11, 2022
    On March 10, Biotime donated 2 million of the SARS-COV-2 Antigen Rapid Qualitative Test Kits to Hong Kong. The increasing numbers of the Covid-19 in Hong Kong have been a big concern for the Chinese Government and its people. The Chinese Government has given full support to Hong Kong in its fight against the Covid-19. All sectors of the society and Hong Kong compatriots are helping each other and assisting Hong Kong in its fight against the Covid-19 in various ways. As a company that has long supported global anti-epidemic efforts through In Vitro Diagnostics, Biotime has actively responded to support Hong Kong in its fight against the COVID-19. We donated 12-million-yuan worth of epidemic prevention materials to Hong Kong. Biotime's Vice President of Operations, Jim Huang, presided over the donation ceremony. Mr. Huang said that as POCT developers, especially during the epidemic, we have a greater responsibility to share the worries and difficulties of our country and compatriots. Biotime COVID-19 antigen tests have played an outstanding role in the UK's epidemic prevention and controlling of the spread of Covid-19. Witnessing the Hong Kong epidemic increasing rapidly, Biotime hoped to play a significant role in Hong Kong's anti-epidemic efforts and assist Hong Kong to win the epidemic prevention and control the spread as soon as possible. ▲vice GM of Operation, Jim Huang Afterward, Biotime contacted Yi Zhiming, a member of the Hong Kong Legislative Council. Mr. Yi expressed his gratitude to the Xiamen Municipal Government and Biotime. He stated that the SARS-COV-2 Antigen Rapid Qualitative Test Kits, once they arrived, Covid-19 test kits will be delivered to the citizens quickly so that a protective wall can be built against the epidemic and protect the health of the Hong Kong citizens. Mr. Yi also mentioned working together will bring Hong Kong back to its former glory ▲ Connect with the senator of Legislative Council of the Hong Kong Special Administrative Region Yi Zhiming. ▲ Dong Zhonghong, Office of the Government of the Hong Kong Special Administrative Region in Fujian. Since Biotime was founded, it has committed itself actively to undertakings such as education, disaster relief, and fulfilling its social responsibility as a company and as well as a form of love to the world. As a result of the epidemic, Biotime has displayed "China's strength" in the prevention and control of epidemics across the globe. ▲ Donor Ceremony
    View More
  • Adlai Nortye and Biotime Announce Technical and Commercial Partnership
    Adlai Nortye and Biotime Announce Technical and Commercial Partnership January 19, 2022
    Adlai Nortye Ltd. (“Adlai Nortye”) and Xiamen Biotime Biotechnology Co., Ltd. (“Biotime”) Announce Technical and Commercial Partnership on PD-L1 Inhibitors, Anti-hTNFR2 Antibody Products and Many Other Products Adlai Nortye Biopharma Co., Ltd. a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with R&D and global clinical operation centers in both China and the United States, has expanded its technical and commercial partnership with Xiamen Biotime Biotechnology Co., Ltd. a Hi-Tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents, and offer the industry’s most comprehensive in vitro diagnostics solutions to more than 60 countries and regions. The agreement aims to boost the development, production and commercialization of the PD-L1 inhibitors AN4005, anti-hTNFR2 antibody products and other products in Greater China and other regions of the world. Under the deal, the total amount of investment has reached several hundreds of millions of yuan which includes the down payment, the milestone payment that triggered by the milestone events and the royalties. The AN4005 Adlai Nortye developed is a drug candidates that made the fastest progress in clinical trials. It shows strong anti-tumour efficacy, good multibinding, high safety and meets clinical and commercial needs,in addition to that, it also shows great potential and might pioneer oral small-molecule inhibitor of PD-L1. AN3025 is a new humanized IgG1anti-hTNFR2 antibody which is in the early part of development of preclinical trial, it’s expected to enhance antitumor immune response which may help to achieved better tumour control and improve treatment. “Indigenous innovation is the core to Biotime, we just create a new business of innovative medicine, increase the research and development funding, take part in the innovative network and try to be a high-quality developer, innovative engineer to the industry.” said Yu Jianping, Executive Secretary of Biotime. “Adlai Nortye is a leading brand of innovative medicine, so this cooperation would be a win-win prospect.” “We are glad to come to an agreement with Biotime who has well-grounded research and technical capabilities, they continue to pursue innovation-driven development and highly value product research. Partnership is expected to begin the process profit-oriented, development of AN4005, AN3025 and other products across the globe. We are confident these products would benefit all the patient in the world and the cooperation would only accelerate the actions we are going to take.” said He Nanhai, Ph.D., Head of Adlai Nortye’s global R&D. About Biotime Established in April 2008, Xiamen Biotime is a Hi-tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents. Biotime has successfully settled the mature medical marketing channels during the past year...
    View More
  • National Day holiday
    National Day holiday September 30, 2021
    This is the official announcement of the National Day of the People's Republic of China. All our customers have been informed that due to the National Day holiday we will be closed on Friday 1st October and will resume normal business on Wednesday 8th October. We salute the founding of our country and the heroic warriors who gave their lives for this country. National Day holiday: October 1 to October 7, 2021 Reopen date: October 8, 2021 During this time, please feel free to call the office if you have any questions about your business. Congratulations and thanks to everyone who has contributed to the success of our business. Xiamen Biotechnology Co., Ltd. 30th September, 2021
    View More
First 1 2 Last
[  A total of  2  pages]
Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.

Home

products

about

contact